Skip to search formSkip to main contentSkip to account menu

refractory plasma cell neoplasm

Known as: Refractory Multiple Myeloma, Refractory Plasma Cell Myeloma, plasma cell neoplasm, refractory 
A plasma cell neoplasm that is resistant to treatment.
National Institutes of Health

Related topics

Related topics

35 relations
AnemiaAtypical lymphocyteB lymphoblastB-Lymphocytes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.
3010Background: To test the safety and efficacy of the CAR T cell modality in relapsed/refractory multiple myeloma (MM), we have… 
2015
2015
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)
![Graphic][1] Introduction : Daratumumab (DARA) is a human anti-CD38 IgG1κ monoclonal antibody that showed synergistic anti… 
Highly Cited
2013
Highly Cited
2013
Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
What is known and objective:  High costs of novel agents increasingly put pressure on limited healthcare budgets. Demonstration… 
Highly Cited
2012
Highly Cited
2012
The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells
DNA cross-linking agents are frequently used in the treatment of multiple myeloma–generating lesions, which activate checkpoint… 
Highly Cited
2011
Highly Cited
2011
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
Purpose: A phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) for the… 
Highly Cited
2010
Highly Cited
2010
Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
8032 Background: Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or relapsed/refractory… 
Highly Cited
2007
Highly Cited
2007
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group…
Thalidomide has direct antimyeloma and immunomodulatory effects. In addition, both thalidomide and metronomic chemotherapy… 
Highly Cited
2005
Highly Cited
2005
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
Bortezomib, a first‐in‐class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma. 
Highly Cited
2002
Highly Cited
2002
The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma.
INTRODUCTION Thalidomide has recently proven to be a useful drug for treatment of refractory and relapsed multiple myeloma… 
Highly Cited
2000
Highly Cited
2000
Thalidomide for resistant and relapsing myeloma
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)